Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe Interaction
Drug interaction information between Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe.
Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe have a documented major interaction in FDA labeling.
FDA drug labeling documents a major-severity interaction between Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
These hepatitis C drugs block the pathways your body uses to remove rosuvastatin, leading to higher levels of the statin in your blood. This can increase your risk for serious side effects.
What To Do
Your doctor should start your rosuvastatin at 5 mg daily and keep the dose at or below 10 mg per day.
FDA Label Information
Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.
Glecaprevir/Pibrentasvir Also Interacts With
- Rifampin major
- Rosuvastatin major
- Cyclosporine moderate
- Darunavir moderate
- Estradiol moderate
Rosuvastatin/Ezetimibe Also Interacts With
- Sofosbuvir/Velpatasvir major
- Febuxostat major
- Rosuvastatin moderate
- Cyclosporine moderate
- Ledipasvir/Sofosbuvir moderate
Frequently Asked Questions
Can I take Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe together?
This is a major interaction. Your doctor should start your rosuvastatin at 5 mg daily and keep the dose at or below 10 mg per day.
How serious is the interaction between Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe?
This interaction is classified as "major" severity by the FDA. Major interactions may be life-threatening or cause serious side effects.
Why do Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe interact?
These hepatitis C drugs block the pathways your body uses to remove rosuvastatin, leading to higher levels of the statin in your blood. This can increase your risk for serious side effects.
Understanding the Glecaprevir/Pibrentasvir and Rosuvastatin/Ezetimibe Interaction
FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Glecaprevir/Pibrentasvir belongs to the NS3/4A/NS5A Inhibitor (HCV) class and Rosuvastatin/Ezetimibe belongs to the Statin / Cholesterol Absorption Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These hepatitis C drugs block the pathways your body uses to remove rosuvastatin, leading to higher levels of the statin in your blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Glecaprevir/Pibrentasvir has 38 total documented interactions on file in this dataset, and Rosuvastatin/Ezetimibe has 12. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should start your rosuvastatin at 5 mg daily and keep the dose at or below 10 mg per day. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Glecaprevir/Pibrentasvir or Rosuvastatin/Ezetimibe based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.